NTRB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

765.00K

+19.09%

-2.130

+1675%

-1.890

+270.59%

Estimates Revision

The market is revising No Change the revenue expectations for Nutriband Inc. (NTRB) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -32.31%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-32.31%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.840

Low

15.00

Averages

15.00

High

15.00

Current: 4.840

Low

15.00

Averages

15.00

High

15.00

Noble Capital Markets

Robert LeBoyer

Buy

Initiates

$13

2025-01-22

Reason

Noble Capital Markets

Robert LeBoyer

Price Target

$13

2025-01-22

Initiates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Nutriband Inc (NTRB.O) is 9.64, compared to its 5-year average forward P/E of -6.12. For a more detailed relative valuation and DCF analysis to assess Nutriband Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.12

Current PE

9.64

Overvalued PE

99.72

Undervalued PE

-111.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.89

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

52.74

Undervalued EV/EBITDA

-56.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

16.30

Current PS

0.00

Overvalued PS

38.16

Undervalued PS

-5.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NTRB News & Events

Events Timeline

No data

News

9.5

11-12NASDAQ.COM

Korro Bio, Inc. (KRRO) Announces Q3 Loss and Falls Short of Revenue Projections

9.5

11-11NASDAQ.COM

Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections

5.0

10-27NASDAQ.COM

Nutriband Co-Founder Gareth Sheridan Reassumes Position as CEO

People Also Watch

Frequently Asked Questions

What is Nutriband Inc (NTRB) stock price today?

The current price of NTRB is 4.84 USD — it has decreased -5.1 % in the last trading day.

What is Nutriband Inc (NTRB)'s business?

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

What is the price predicton of NTRB Stock?

What is Nutriband Inc (NTRB)'s revenue for the last quarter?

Nutriband Inc revenue for the last quarter amounts to 346.06K USD, decreased -46.41 % YoY.

What is Nutriband Inc (NTRB)'s earnings per share (EPS) for the last quarter?

Nutriband Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Nutriband Inc (NTRB)'s fundamentals?

How many employees does Nutriband Inc (NTRB). have?

Nutriband Inc (NTRB) has 3 emplpoyees as of December 16 2025.

What is Nutriband Inc (NTRB) market cap?

Today NTRB has the market capitalization of 58.93M USD.